Immunity Boosting Combination Therapy for Myelodysplastic Syndrome Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Eligible to Receive Aggregate Income of $13.75M and Royalties of up to $12.50M - Form 8-K marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Promising Combination Therapy for Tripple Negative Breast Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, Potential Income of $13.75M and Royalties of up to $12.50M - Form 8-K marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Investors are closely eyeing Biopharma Healthcare stocks following impressive performances this week. Dive into the analysis of five stocks, with three flaunting notable gains and two potentially.
ABVC BioPharma Inc (NASDAQ: ABVC) and its subsidiary BioLite Inc received an aggregate of 46 million shares from AiBtl BioPharma Inc as its first milestone payment under a global licensing agreement.